Medicare Enrolled
Dr. Benjamin Leach, M.D.
Hematology & Oncology · Mission Hills, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Leach from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Leach?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Leach
Dr. Benjamin Leach is a hematology & oncology specialist in Mission Hills, CA, with 14 years of NPI registration. Based on federal Medicare data, Dr. Leach performed 55,286 Medicare services across 1,245 unique beneficiaries.
Between the years covered by Open Payments, Dr. Leach received a total of $14,302 from 35 pharmaceutical and/or device companies across 135 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Leach is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 14 years in practice
▲ Top 14% volume in CA
$14,302 industry payments
Medicare Practice Summary
Medicare Utilization ↗55,286
Medicare services
Top 14% in CA for hematology & oncology
1,245
Unique beneficiaries
$18
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~3,949 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
15,700 | $2 | $10 |
| Pembrolizumab injection (Keytruda) | 13,400 | $43 | $193 |
| Paclitaxel chemotherapy injection | 9,411 | $0 | $0 |
| Anti-nausea injection (aprepitant) | 6,240 | $1 | $6 |
| Denosumab injection (Prolia/Xgeva) | 5,040 | $19 | $83 |
| Anti-nausea injection (ondansetron/Zofran) | 948 | $0 | $0 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
824 | $0 | $0 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
552 | $71 | $318 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
377 | $2 | $9 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
318 | $149 | $672 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
289 | $65 | $284 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
287 | $100 | $481 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
272 | $14 | $93 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
254 | $121 | $606 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
174 | $53 | $341 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
154 | $99 | $410 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
145 | $12 | $81 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
127 | $144 | $630 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 124 | $133 | $607 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
93 | $59 | $295 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
72 | $31 | $134 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
68 | $26 | $134 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
68 | $81 | $479 |
| New patient office visit, complex (60-74 min) | 48 | $177 | $821 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
47 | $1 | $3 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
46 | $53 | $269 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
39 | $25 | $109 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
38 | $17 | $81 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
35 | $26 | $147 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
31 | $1 | $23 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
25 | $18 | $88 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
24 | $24 | $103 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
16 | $1 | $5 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.8% high complexity
96.1% medium
3.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$14,302
Total received (2018-2024)
Avg $2,043/year across 7 years
Top 27% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
35
Companies
135
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$10,721 (75.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,499 (24.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$82 (0.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$5,467
2023
$536
2022
$2,005
2021
$2,455
2020
$2,160
2019
$774
2018
$906
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
GENZYME CORPORATION
$2,921
AstraZeneca Pharmaceuticals LP
$2,220
Kite Pharma, Inc.
$150
ImmunoGen, Inc.
$87
INTUITIVE SURGICAL, INC.
$56
Celgene Corporation
$17
Takeda Pharmaceuticals U.S.A., Inc.
$16
Top 3 companies account for 96.8% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$4,323
Novartis Pharmaceuticals Corporation
$3,556
GENZYME CORPORATION
$3,531
Genentech USA, Inc.
$349
PFIZER INC.
$275
E.R. Squibb & Sons, L.L.C.
$222
BeiGene USA, Inc.
$220
GlaxoSmithKline, LLC.
$215
Amgen Inc.
$188
Kite Pharma, Inc.
$150
JAZZ PHARMACEUTICALS INC.
$144
Seattle Genetics, Inc.
$129
ImmunoGen, Inc.
$87
Merck Sharp & Dohme Corporation
$86
Array BioPharma Inc.
$81
Takeda Pharmaceuticals U.S.A., Inc.
$71
Puma Biotechnology, Inc.
$63
Janssen Biotech, Inc.
$58
INTUITIVE SURGICAL, INC.
$56
Regeneron Healthcare Solutions, Inc.
$51
Gilead Sciences, Inc.
$46
Bayer HealthCare Pharmaceuticals Inc.
$46
Boehringer Ingelheim Pharmaceuticals, Inc.
$44
Eisai Inc.
$42
Foundation Medicine, Inc.
$41
Incyte Corporation
$36
Sirtex Medical Inc
$28
TESARO, Inc.
$28
Pharmacyclics LLC, An AbbVie Company
$24
Antares Pharma, Inc.
$24
Clovis Oncology, Inc.
$21
Seagen Inc.
$18
BTG International, Inc.
$17
Celgene Corporation
$17
INSYS Therapeutics Inc
$15
Top 3 companies account for 79.8% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · Aliqopa · Aranesp · Avastin · BAVENCIO · BRUKINSA · Braftovi · CABLIVI · DARZALEX · DEFITELIO · Da Vinci Surgical System · ELAHERE · ELIQUIS · ELITEK · EMPLICITI · FOUNDATIONONE · FRUZAQLA · GILOTRIF · Halaven · IBRANCE · INLYTA · Imbruvica · JAKAFI · KEYTRUDA · Kyprolis · LIBTAYO · LORBRENA · LYNPARZA · Lenvima · MEKINIST · NINLARO · Nerlynx · Neulasta · OPDIVO · Otrexup · PIQRAY · PROMACTA · Perjeta · REBLOZYL · Rubraca · SANDOSTATIN · SARCLISA · SIR-Spheres Microspheres · SUTENT · SYNDROS · Stivarga · TABRECTA · TAGRISSO · TALZENNA · TECENTRIQ · VORAXAZE · XALKORI · XTANDI · Yescarta · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (75%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
Hematology & oncology specialists within 10 mi
286
Per 100K population
2.9
County median income
$87,760
Nearest hospital
KAISER FOUNDATION HOSPITAL - PANORAMA CITY
3.1 mi
3.1 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Leach is a mixed practice specialist, with above-average Medicare volume (top 14% in CA), with consulting-driven industry engagement.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Leach experienced with darbepoetin injection (aranesp) for anemia?
Based on Medicare claims data, Dr. Leach performed 15,700 darbepoetin injection (aranesp) for anemia services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Leach receive payments from pharmaceutical companies?
Yes. Dr. Leach received a total of $14,302 from 35 companies across 135 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Leach's costs compare to other hematology & oncology specialists in Mission Hills?
Dr. Leach's average Medicare payment per service is $18. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Leach) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Mission Hills
Browse hematology & oncology specialists in Mission Hills ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology